Patents by Inventor Jerry Murry

Jerry Murry has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20180319738
    Abstract: The present invention is concerned with novel processes for the preparation of (+)-1-(3,4-dichlorophenyl)-3-azabicyclo[3.1.0]hexane or a pharmaceutically acceptable salt thereof, and (?)-1-(3,4-dichlorophenyl)-3-azabicyclo[3.1.0]hexane or a pharmaceutically acceptable salt thereof. These compounds have pharmaceutical utility and are known to be useful for treating e.g., depression, anxiety disorders, eating disorders and urinary incontinence.
    Type: Application
    Filed: November 22, 2017
    Publication date: November 8, 2018
    Inventors: Jerry A. MURRY, Edward G. CORLEY, Feng XU, Bryon SIMMONS
  • Publication number: 20170233333
    Abstract: The present invention is concerned with novel processes for the preparation of (+)-1-(3,4-dichlorophenyl)-3-azabicyclo[3.1.0]hexane or a pharmaceutically acceptable salt thereof, and (?)-1-(3,4-dichlorophenyl)-3-azabicyclo[3.1.0]hexane or a pharmaceutically acceptable salt thereof. These compounds have pharmaceutical utility and are known to be useful for treating e.g., depression, anxiety disorders, eating disorders and urinary incontinence.
    Type: Application
    Filed: December 2, 2016
    Publication date: August 17, 2017
    Inventors: Jerry A. MURRY, Edward G. CORLEY, Feng XU, Bryon SIMMONS
  • Patent number: 9527813
    Abstract: The present invention is concerned with novel processes for the preparation of (+)-1-(3,4-dichlorophenyl)-3-azabicyclo[3.1.0]hexane or a pharmaceutically acceptable salt thereof, and (?)-1-(3,4-dichlorophenyl)-3-azabicyclo[3.1.0]hexane or a pharmaceutically acceptable salt thereof. These compounds have pharmaceutical utility and are known to be useful for treating e.g., depression, anxiety disorders, eating disorders and urinary incontinence.
    Type: Grant
    Filed: July 18, 2013
    Date of Patent: December 27, 2016
    Assignee: EUTHYMICS BIOSCIENCE, INC.
    Inventors: Jerry A. Murry, Edward G. Corley, Feng Xu, Bryon Simmons
  • Publication number: 20140163240
    Abstract: The present invention is concerned with novel processes for the preparation of (+)-1-(3,4-dichlorophenyl)-3-azabicyclo[3.1.0]hexane or a pharmaceutically acceptable salt thereof, and (?)-1-(3,4-dichlorophenyl)-3-azabicyclo[3.1.0]hexane or a pharmaceutically acceptable salt thereof. These compounds have pharmaceutical utility and are known to be useful for treating e.g., depression, anxiety disorders, eating disorders and urinary incontinence.
    Type: Application
    Filed: July 18, 2013
    Publication date: June 12, 2014
    Inventors: Jerry A. Murry, Edwin G. Corley, Feng Xu, Bryon Simmons
  • Patent number: 8552193
    Abstract: The present invention is directed to alternative forms of the title phosphodiesterase 4 inhibitor which has the structural formula shown immediately below:
    Type: Grant
    Filed: March 31, 2010
    Date of Patent: October 8, 2013
    Assignee: Merck Sharp & Dohme Corp.
    Inventors: Sophie-Dorothee Clas, Rafik Naccache, Hongshi Yu, Jerry Murry, Narayan Vanankaval
  • Publication number: 20130231363
    Abstract: The present invention is directed to alternative forms of the title phosphodiesterase 4 inhibitor which has the structural formula shown immediately below:
    Type: Application
    Filed: March 31, 2010
    Publication date: September 5, 2013
    Inventors: Sophie-Dorothee Clas, Rafik Naccache, Hongshi Yu, Jerry Murry, Narayan Variankaval
  • Publication number: 20120142940
    Abstract: The present invention is concerned with novel processes for the preparation of (+)-1-(3,4-dichlorophenyl)-3-azabicyclo[3.1.0]hexane or a pharmaceutically acceptable salt thereof, and (?)-1-(3,4-dichlorophenyl)-3-azabicyclo[3.1.0]hexane or a pharmaceutically acceptable salt thereof. These compounds have pharmaceutical utility and are known to be useful for treating e.g., depression, anxiety disorders, eating disorders and urinary incontinence.
    Type: Application
    Filed: February 3, 2012
    Publication date: June 7, 2012
    Inventors: Jerry A. MURRY, Edward G. Corley, Feng Xu, Bryon Simmons
  • Patent number: 8193216
    Abstract: The present invention is directed to novel polymorphic forms of the compound 4,5,6,7-tetrahydroisoxazolo[5,4-c]pyridin-3-ol hydrate (gaboxadol monohydrate). The invention is further concerned with pharmaceutical compositions containing the polymorphic forms as an active ingredient, methods for treatment of disorders susceptible to amelioration by GABAA receptor agonism with the polymorphic forms, and processes for the preparation of the polymorphic forms.
    Type: Grant
    Filed: August 16, 2011
    Date of Patent: June 5, 2012
    Assignee: H. Lundbeck A/S
    Inventors: Daniel J. Kumke, Jerry A. Murry, Bryon L. Simmons, Feng Xu
  • Patent number: 8183293
    Abstract: Compounds, pharmaceutical compositions and methods are provided that are useful in the treatment of inflammatory and immune-related diseases and conditions. In particular, the invention provides compounds which modulate the function and/or expression of proteins involved in atopic diseases, inflammatory conditions and cancer. The subject compounds are carboxylic acid derivatives.
    Type: Grant
    Filed: December 18, 2008
    Date of Patent: May 22, 2012
    Assignee: Amgen Inc.
    Inventors: Mark Grillo, An-Rong Li, Jiwen Liu, Julio C. Medina, Yongli Su, Yingcai Wang, Janan Jona, Alan Allgeier, Jacqueline Milne, Jerry Murry, Joseph F. Payack, Thomas Storz
  • Patent number: 8129413
    Abstract: The present invention relates to a process for producing N-{(1S)-1-[2-(1-{[(3S,4R)-1-tert-butyl-4-(2,4-difluorophenyl)pyrrolidin-3-yl]carbonyl}piperidin-4-yl)-5-chlorophenyl]ethyl}acetamide, and novel crystalline salts, hydrates, solvates, and polymorphic forms thereof.
    Type: Grant
    Filed: June 23, 2006
    Date of Patent: March 6, 2012
    Assignee: Merck Sharp & Dohme Corp.
    Inventors: Ralph Calabria, Yu Cheng, Russell R. Ferlita, Ashkan Kamali, Jerry A. Murry, David Mathre, Andrey V. Peresypkin, Karen Thompson, Jian Wang, Robert M. Wenslow
  • Publication number: 20110301190
    Abstract: The present invention is directed to novel polymorphic forms of the compound 4,5,6,7-tetrahydroisoxazolo[5,4-c]pyridin-3-ol hydrate (gaboxadol monohydrate). The invention is further concerned with pharmaceutical compositions containing the polymorphic forms as an active ingredient, methods for treatment of disorders susceptible to amelioration by GABAA receptor agonism with the polymorphic forms, and processes for the preparation of the polymorphic forms.
    Type: Application
    Filed: August 16, 2011
    Publication date: December 8, 2011
    Applicant: H. LUNDBECK A/S
    Inventors: Daniel J. Kumke, Jerry A. Murry, Bryon L. Simmons, Feng Xu
  • Publication number: 20110295020
    Abstract: The present invention is concerned with novel processes for the preparation of (+)-1-(3,4-dichlorophenyl)-3-azabicyclo[3.1.0]hexane or a pharmaceutically acceptable salt thereof, and (?)-1-(3,4-dichlorophenyl)-3-azabicyclo[3.1.0]hexane or a pharmaceutically acceptable salt thereof. These compounds have pharmaceutical utility and are known to be useful for treating e.g., depression, anxiety disorders, eating disorders and urinary incontinence.
    Type: Application
    Filed: August 10, 2011
    Publication date: December 1, 2011
    Inventors: Jerry A. MURRY, Edward G. CORLEY, Feng XU, Bryon SIMMONS
  • Publication number: 20110245290
    Abstract: The present invention is directed to alternative forms of the title phosphodiesterase 4 inhibitor which has the structural formula shown immediately below:
    Type: Application
    Filed: March 31, 2010
    Publication date: October 6, 2011
    Inventors: Sophie-Dorothee Clas, Rafik Naccache, Hongshi Yu, Jerry Murry, Narayan Variankaval
  • Patent number: 8022084
    Abstract: The present invention is directed to novel polymorphic forms of the compound 4,5,6,7-tetrahydroisoxazolo[5,4-c]pyridin-3-ol hydrate (gaboxadol monohydrate). The invention is further concerned with pharmaceutical compositions containing the polymorphic forms as an active ingredient, methods for treatment of disorders susceptible to amelioration by GABAA receptor agonism with the polymorphic forms, and processes for the preparation of the polymorphic forms.
    Type: Grant
    Filed: January 26, 2006
    Date of Patent: September 20, 2011
    Assignee: H. Lundbeck A/S
    Inventors: Daniel J. Kumke, Jerry A. Murry, Bryon L. Simmons, Feng Xu
  • Publication number: 20100298574
    Abstract: The present invention is concerned with novel processes for the preparation of (+)-1-(3,4-dichlorophenyl)-3-azabicyclo[3.1.0]hexane or a pharmaceutically acceptable salt thereof, and (?)-1-(3,4-dichlorophenyl)-3-azabicyclo[3.1.0]hexane or a pharmaceutically acceptable salt thereof. These compounds have pharmaceutical utility and are known to be useful for treating e.g., depression, anxiety disorders, eating disorders and urinary incontinence.
    Type: Application
    Filed: May 18, 2010
    Publication date: November 25, 2010
    Inventors: Jerry A. Murry, Edward G. CORELY, Feng Xu, Bryon Simmons
  • Publication number: 20100204486
    Abstract: The present invention is concerned with novel processes for the preparation of (+)-1-aryl-3-azabicyclo[3,10]hexanes or a pharmaceutically acceptable salt thereof, and (?)-1-aryl-3-azabicyclo[3,10]hexanes or a pharmaceutically acceptable salt thereof. These compounds have pharmaceutical utility and are known to be useful for treating e.g., pain, depression, anxiety disorders, eating disorders and urinary incontinence.
    Type: Application
    Filed: April 27, 2007
    Publication date: August 12, 2010
    Applicant: MERCK & CO., INC.
    Inventors: Edward G. Corley, Jerry A. Murry, Bryon Simmons, Feng Xu
  • Publication number: 20090275659
    Abstract: Compounds, pharmaceutical compositions and methods are provided that are useful in the treatment of inflammatory and immune-related diseases and conditions. In particular, the invention provides compounds which modulate the function and/or expression of proteins involved in atopic diseases, inflammatory conditions and cancer. The subject compounds are carboxylic acid derivatives.
    Type: Application
    Filed: December 18, 2008
    Publication date: November 5, 2009
    Applicant: Amgen Inc.
    Inventors: Mark Grillo, An-Rong Li, Jiwen Liu, Julio C. Medina, Yongli Su, Yingcai Wang, Janan Jona, Alan Allgeier, Jacqueline Milne, Jerry Murry, Joseph F. Payack, Thomas Storz
  • Publication number: 20090233967
    Abstract: The present invention relates to a process for producing N-{(1S)-1-[2-(1-{[(3S,4R)-1-tert-butyl-4-(2,4-difluorophenyl)pyrrolidin-3-yl]carbonyl}piperidin-4-yl)-5-chlorophenyl]ethyl}acetamide, and novel crystalline salts, hydrates, solvates, and polymorphic forms thereof.
    Type: Application
    Filed: June 23, 2006
    Publication date: September 17, 2009
    Inventors: Ralph Calabria, Yu Cheng, Russell R. Ferlita, Ashkan Kamali, Jerry A. Murry, David Mathre, Andrey V. Peresypkin, Karen Thompson, Jian Wang, Robert M. Wenslow
  • Publication number: 20090012061
    Abstract: The present invention relates to a method of treating cellular proliferative diseases, in particular cancer, which comprises administering a modulator of the activity of the mitotic kinesin KSP, wherein the activity of the KSP modulator is dependent on the presence of microtubules. It is believed that the KSP modulators utilized in the instant method bind to the KSP protein in a previously unreported manner, since the compounds do not bind competitively with respect to either microtubules or ATP, the substrates of KSP. The modulators useful in the instant methods are furthermore not active against the non-microtubule stimulated activity of KSP. Cellular proliferative diseases that may be treated using the method disclosed herein are, for example cancer, hyperplasias, restenosis, cardiac hypertrophy, immune disorders and inflammation.
    Type: Application
    Filed: September 9, 2005
    Publication date: January 8, 2009
    Inventors: Timothy A. Blizzard, Carolyn A. Buser-Doepner, Douglas E. Frantz, Kelly Hamilton, Myle Hoang, Ling Lee, Christopher R. Moyes, Jerry A. Murry, Arash Soheili
  • Publication number: 20080262029
    Abstract: The present invention is directed to novel acid salt forms and base salt forms of the compound gabaoxadol (4,5,6,7-tetrahydroisoxazolo[5,4-c]pyridin-3-ol) and hydrates, solvates and polymorphic forms thereof. The invention is further concerned with pharmaceutical compositions containing the salt forms as an active ingredient, methods for treatment of disorders susceptible to amelioration by GABAA receptor agonism with the salt forms, and processes for the preparation of the salt forms.
    Type: Application
    Filed: April 25, 2006
    Publication date: October 23, 2008
    Applicant: H. Lundbeck A/S
    Inventors: Louis S. Crocker, Jerry A. Murry, Karthik Nagapudi, Kara Beth Rubin